Vivesto — Capital/Financing Update 2012

Oct 25, 2012

News Details

Corporate | 25 October 2012 16:52

Prospectus regarding Oasmia Pharmaceutical’s rights issue is now available

Oasmia Pharmaceutical AB

25.10.2012 16:52

The Board of Directors of Oasmia Pharmaceutical AB (publ) ('Oasmia') has
prepared a prospectus for the purpose of the rights issue, which was announced
on October 18, 2012.

Uppsala, Sweden, 2012-10-25 16:51 CEST (GLOBE NEWSWIRE) --

The prospectus has today been approved by and registered with the Swedish
Financial Supervisory Authority (Swe. Finansinspektionen) and is now available
on Oasmia's website (www.oasmia.com), Carnegie Investment Bank AB's website
(www.carnegie.se) and the Swedish Financial Supervisory Authority's website
(www.fi.se). The prospectus can also be ordered from Carnegie Investment Bank
AB during business hours by telephone +46 (0)8 5886 8660.

The information above has been made public in accordance with the Securities
Market Act and/or the Financial Instruments Trading Act. The information was
published at 16.50 on October 25, 2012.

IMPORTANT INFORMATION
The information in this press release is not for release, publication or
distribution, directly or indirectly, in or into Australia, Canada, Hong Kong,
Japan, New Zealand, Singapore, South Africa or the United States or in any
jurisdiction in which the distribution of this release would be unlawful. The
distribution of this press release in certain other jurisdictions may be
restricted. The information in this press release shall not constitute an offer
to sell or the solicitation of an offer to buy any securities in Oasmia in any
jurisdiction.

This press release does not constitute or form part of an offer or solicitation
to purchase or subscribe for securities in the United States. The securities
referred to herein may not be offered or sold in the United States absent
registration or an exemption from registration as provided in the U.S.
Securities Act of 1933, as amended. Oasmia does not intend to register any
portion of the offering of the securities in the United States or to conduct a
public offering of the securities in the United States. Copies of this
announcement are not being made and may not be distributed or sent into,
Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or
the United States or in any jurisdiction in which the distribution of this
release would be unlawful.

This document has not been approved by any regulatory authority. This document
is an advertisement and not a prospectus and investors should not subscribe
for, or purchase any securities referred to in this document, except on the
basis of information provided in the prospectus published by Oasmia and
available on its web site. Oasmia has not authorized any offer to the public of
shares or rights in any Member State of the European Economic Area other than
Sweden and any other jurisdiction into which the offering of shares or rights
has been passported or in which other exemptions are applicable. With respect
to each Member State of the European Economic Area other than Sweden (and any
other jurisdiction into which the offering of shares or rights has been
passported) and which has implemented the Prospectus Directive (each, a
'Relevant Member State'), no action has been undertaken to date to make an
offer to the public of shares or rights requiring a publication of a prospectus
in any Relevant Member State. As a result, the shares or rights may only be
offered in a Relevant Member State:

(a) to legal entities which are authorized or regulated to operate in the
financial markets or, if not so authorized or regulated, whose corporate
purpose is solely to invest in securities;

(b) to any legal entity meeting two or more of the following criteria: (1) a
balance sheet total pursuant to the balance sheet equivalent to not less than
EUR 20 million; (2) net turnover pursuant to the balance sheet equivalent to
not less than EUR 40 million; and shareholders' equity pursuant to the balance
sheet equivalent to not less than EUR 2 million; or

(c) in any other circumstances, not requiring Oasmia to publish a prospectus as
provided under Article 3(2) of the Prospectus Directive.

For the purposes hereof, the expression an 'offer to the public of Shares or
Rights' in any Relevant Member State means the communication in any form and by
any means of sufficient information on the terms of the offer and the shares or
rights to be offered so as to enable an investor to decide to purchase any
securities, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State and the expression
'Prospectus Directive' means Directive 2003/71/EC as amended and includes any
relevant implementing measure in each Relevant Member State.

Carnegie is acting for Oasmia and no one else in connection with the rights
offering and will not be responsible to anyone other than Oasmia for providing
the protections afforded to its clients or for providing advice in relation to
the rights offering and/or any other matter referred to in this announcement.

Carnegie accepts no responsibility whatsoever and makes no representation or
warranty, express or implied, for the contents of this announcement, including
its accuracy, completeness or verification or for any other statement made or
purported to be made by it, or on its behalf, in connection with Oasmia and the
new shares, or the rights offering, and nothing in this announcement is, or
shall be relied upon as, a promise or representation in this respect, whether
as to the past or future. Carnegie accordingly disclaims to the fullest extent
permitted by law all and any responsibility and liability whether arising in
tort, contract or otherwise which it might otherwise have in respect of this
announcement or any such statement.

This press release contains forward-looking statements, which are statements
related to future events. In this context, forward-looking statements often
address Oasmia's expected future business and financial performance, and often
contain words such as 'expect', 'anticipate', 'intend', 'plan', 'believe',
'seek', or 'will'. Forward-looking statements by their nature address matters
that are, to different degrees, uncertain and can be influenced by many
factors, including the behaviour of financial markets, fluctuations in interest
and exchange rates, commodity and equity prices and the value of financial
assets; the impact of regulation and regulatory, investigative and legal
actions; strategic actions; and numerous other matters of national, regional
and global scale, including those of a political, economic, business and
competitive nature. These factors may cause Oasmia's actual future results to
be materially different than those expressed in its forward-looking statements.
Oasmia does not undertake to update its forward-looking statements.

You are advised to read this announcement and the prospectus and the
information incorporated by reference therein, in their entirety for a further
discussion of the factors that could affect the Oasmia's future performance and
the industries in which it operates. In light of these risks, uncertainties and
assumptions, the events described in the forward-looking statements in this
announcement may not occur.

Click on, or paste the following link into your web browser, to view the associated documents

https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=407634

News Source: NASDAQ OMX

25.10.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Oasmia Pharmaceutical AB

          Sweden

Phone:
Fax:
E-mail:
Internet:
ISIN: SE0000722365
WKN:

End of Announcement DGAP News-Service

---